The court appeal Pfizer won Feb. 13 helped set the boundaries on the issue, which in this case involved a claim by the University of Rochester that it had discovered a way to treat inflammation without stomach problems by inhibiting the Cox-2 enzyme. The court ruled the university, which had described a way of finding such drugs, did not sufficiently describe a new drug and could not stop Pfizer's own Cox-2 inhibitor, Celebrex.

Full Story:

Related Summaries